Pfizer lays out ambitious vision for cancer portfolio in bid to reinvigorate its business

Pfiz­er hopes that its cur­rent pipeline could de­liv­er at least eight can­cer block­buster drugs by 2030 as part of its strat­e­gy to dou­ble down on its on­col­o­gy busi­ness af­ter the Seagen ac­qui­si­tion.

In De­cem­ber, the phar­ma gi­ant closed the $43 bil­lion ac­qui­si­tion of the an­ti­body-drug con­ju­gate de­vel­op­er and has since merged Seagen with its es­tab­lished on­col­o­gy di­vi­sion. At its can­cer in­no­va­tion day on Thurs­day, CEO Al­bert Bourla said the new­ly-struc­tured or­ga­ni­za­tion “unites the best from Pfiz­er and Seagen to be­come some­thing greater.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.